Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
|Articles|March 9, 2011
Gateway 2011: Hospira One 2 One
Advertisement
Your online Gateway to Hospira One 2 One in 2011
275 North Field Drive
Lake Forest, Illinois, U.S.A. 60045
Call +1-224-212-2267
Don't miss Hospira One 2 One at BIO 2011, June 27-30, Washington, D.C.
About Hospira One 2 One
Hospira is a global specialty pharmaceutical and medication delivery company dedicated to developing, manufacturing and marketing healthcare products that help improve the productivity, safety and efficacy of patient care. The company’s One 2 One business is a world leader in the custom development and manufacture of sterile injectable products packaged in vials, prefilled syringes, cartridges, flexible containers and ampules.
We offer product development and contract manufacturing services at our nine worldwide facilities. Whether your product is a small molecule or advanced biologic, our highly qualified personnel in every world-class facility ensure quality, capacity and security of supply.
Visit our Stand: 4640
We would like to invite you to meet us at stand 4640 to discuss partnering and business development opportunities.
For more information:
one2one@hospira.com
Advertisement
Related to this article
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Tavapadon Sets Development Benchmark for Parkinson's
2
KRAS G12D Inhibitor's $2.13B Deal Tests Cross-Border Tech Transfer
3
Weekly Basal Insulin Efsitora: A New Biologics CMC Benchmark
4
PharmTech’s Weekly Roundup—September 25, 2026
5